Nykredit A S Takes $3.42 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Nykredit A S acquired 39,716 Zimmer Biomet shares worth approximately $3.42 million during the second quarter. Institutional investors collectively own 88.89% of the company.
• Zimmer Biomet exceeded quarterly earnings expectations, reporting $2.07 in EPS and $2.18 billion in revenue, with revenue rising 4.8% year over year. The company issued fiscal 2026 EPS guidance of $8.47–$8.59.
• The company declared a quarterly dividend of $0.24 per share, equivalent to a $0.96 annualized payout and a 1.0% yield. Analysts have an overall “Hold” rating with a consensus price target of $104.42.

Nykredit A S bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 39,716 shares of the medical equipment provider's stock, valued at approximately $3,419,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. DV Equities LLC bought a new stake in Zimmer Biomet in the fourth quarter worth $25,000. Tacita Capital Inc bought a new position in Zimmer Biomet during the second quarter valued at $26,000. Monetary Solutions Ltd purchased a new position in shares of Zimmer Biomet in the 4th quarter worth $30,000. Ancora Advisors LLC purchased a new position in shares of Zimmer Biomet in the 2nd quarter worth $29,000. Finally, Gen Wealth Partners Inc bought a new stake in shares of Zimmer Biomet in the 4th quarter worth about $31,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $97.94 on Monday. The company has a market capitalization of $18.68 billion, a P/E ratio of 23.83, a P/E/G ratio of 1.85 and a beta of 0.47. The company's 50-day simple moving average is $94.82 and its two-hundred day simple moving average is $91.61. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $106.88. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the firm posted $2.07 earnings per share. The company's revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet's payout ratio is 23.36%.

Analysts Set New Price Targets

A number of research analysts recently commented on ZBH shares. Royal Bank Of Canada increased their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday, August 6th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research note on Thursday, August 6th. Wall Street Zen downgraded Zimmer Biomet from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Zacks Research upgraded Zimmer Biomet from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 25th. Finally, UBS Group reissued a "buy" rating and set a $120.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $104.42.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source